We sought to evaluate the muscle metaboreflex in heart failure with reduced ejection fraction (HFrEF) patients, with an emphasis on the interaction between cardiac and peripheral vascular haemodynamics across multiple levels of metaboreceptor activation. In 23 HFrEF patients (63 ± 2 years of age) and 15 healthy control subjects (64 ± 3 years of age), we examined changes in mean arterial pressure, cardiac output, systemic vascular conductance, effective arterial elastance, stroke work and forearm deoxyhaemoglobin concentration during metaboreceptor activation elicited by postexercise circulatory occlusion (PECO) after three levels of static-intermittent handgrip exercise (15, 30 and 45% maximal voluntary contraction). Across workloads, the metaboreflex-induced increase in deoxyhaemoglobin and mean arterial pressure were similar between groups. However, in control subjects, the pressor response was driven by changes (Δ) in cardiac output (Δ495 ± 155, Δ564 ± 156 and Δ666 ± 217 ml min −1 ), whereas this change was accomplished by intensity-dependent reductions in systemic vascular conductance in patients with HFrEF (Δ−4.9 ± 1.5, Δ−9.1 ± 1.9 and Δ−12.7 ± 1.8 ml min mmHg −1 ). This differential response contributed to the exaggerated increases in effective arterial elastance in HFrEF patients compared with control subjects, coupled with a blunted response in stroke work in the HFrEF patients. Together, these findings indicate a preserved role of the metaboreflex-induced pressor response in HFrEF but suggest that this response is governed by changes in the peripheral circulation. The net effect of this response appears to be maladaptive, as it places a substantial haemodynamic load on the left ventricle that may exacerbate left ventricular systolic dysfunction and contribute to exercise intolerance in this patient population.
INTRODUCTION
Heart failure with reduced ejection fraction (HFrEF) is a clinical syndrome that is commonly linked to exercise intolerance (Sullivan & Hawthorne, 1995; Wilson, Martin, Ferraro, & Weber, 1983) .
Although there are many contributing factors to exercise intolerance in this patient population, maladaptation of skeletal muscle has been increasingly recognized, with specific interest focused on the muscle metaboreflex. Activation of this reflex pathway is mediated c 2018 The Authors. Experimental Physiology c 2018 The Physiological Society by metabolically sensitive group IV afferent fibres (metaboreceptors) originating in skeletal muscle, which increase efferent sympathetic nervous system activity in an effort to augment perfusion of the exercising skeletal muscle through increases in arterial blood pressure (ABP; Amann et al., 2011; Crisafulli et al., 2007; O'Leary & Augustyniak, 1998) . Whether the metaboreflex is altered in HFrEF patients remains an ongoing topic of debate (Middlekauff & Sinoway, 2007; Piepoli & Coats, 2007) , with evidence for both similar (Carrington, Fisher, Davies, & White, 2001; Kon, Nakamura, Arakawa, & Hiramori, 2004; Experimental Physiology. 2018; 103:807-818. wileyonlinelibrary.com/journal/eph
New Findings

• What is the central question of this research?
Do patients with heart failure with reduced ejection fraction (HFrEF) exhibit a greater dependence on cardiac or peripheral vascular haemodynamics across multiple levels of muscle metaboreflex activation provoked by postexercise circulatory occlusion?
• What is the main finding and its importance?
The metaboreflex-induced pressor response in HFrEF patients is governed almost entirely by the peripheral circulation, which places a substantial haemodynamic load on the failing heart. This maladaptive response exacerbates the disease-related impairment of systolic function that is a hallmark feature of HFrEF and may therefore contribute to exercise intolerance in this patient group. Notarius, Atchison, & Floras, 2001; Sterns et al., 1991) and exaggerated (Piepoli & Coats, 2007; Piepoli et al., 1996 Piepoli et al., , 1999 Shoemaker, Kunselman, Silber, & Sinoway, 1998; Silber et al., 1998 ) reflex increases in mean arterial blood pressure (MAP) during metaboreflex activation.
These disparate findings suggest that significant uncertainty remains regarding disease-related changes in the muscle metaboreflex in HFrEF patients and the contribution of this reflex to the cardiovascular response to exercise.
Beyond the simple determination of the pressor response, further insight into the importance of metaboreceptor activation in patients with HFrEF may be gained by considering the relative contribution of changes in cardiac [i.e. cardiac output (CO)] and peripheral vascular [i.e.
systemic vascular conductance (SVC)] haemodynamics to the increase in MAP in these patients. Interestingly, in an animal model of systolic heart failure (HF), the contribution of these factors to the overall metaboreflex-induced pressor response has been documented to be solely attributable to a reduction in SVC across exercise intensities (Hammond et al., 2000) . This is vastly different from the response observed in healthy animals, where the metaboreflex-induced increase in MAP is predominantly attributable to an increase in CO at low to moderate exercise intensities, with a shift towards a reliance on SVC to increase MAP only during high-intensity efforts, when the ability to increase CO is compromised (Augustyniak, Collins, Ansorge, Rossi, & O'Leary, 2001) . In humans, only one study to date has examined cardiac and peripheral vascular contributions to the metaboreflex in HFrEF. In that study, Crisafulli et al. (2007) reported a metaboreflexinduced increase in MAP that was predominantly driven by an increase in CO in healthy individuals and by a reduction in SVC in patients with HFrEF, suggesting a greater role of the peripheral vasculature in governing the pressor response. However, that study included only one level of metaboreceptor activation, leaving uncertainty regarding the differential nature of the response that has been demonstrated in an animal model of systolic HF (Hammond et al., 2000) .
Whether the metaboreflex-mediated increase in MAP is achieved by cardiac or peripheral vascular mechanisms may be of functional significance in HFrEF patients, as this reflex may further stress cardiac muscle through a substantial increase in afterload. Indeed, SVC, a measure of systemic vascular tone, represents the non-pulsatile component of arterial afterload Yin & Avolio, 1987) , and considering that patients with HFrEF are known to be afterload sensitive (Asanoi, Sasayama, & Kameyama, 1989; Kameyama, Asanoi, Ishizaka, & Sasayama, 1991; Schwartzenberg et al., 2012) , these patients can experience severe impairments in left ventricular systolic function when arterial afterload is increased (Kameyama et al., 1991 
METHODS
Ethical approval
Subjects
Twenty-three New York Heart Association class II-III HFrEF patients (22 males and one female) and 15 healthy control subjects (14 males and one female) of similar age were recruited either by word of mouth or in the HF clinics at the University of Utah Health Sciences
Center and the Salt Lake City Veterans Affairs Medical Center. All subjects were non-smokers, and control subjects were not taking any prescription medication and were free of overt cardiovascular disease, as indicated by a health history questionnaire. All studies were performed in a thermoneutral environment, with subjects reporting to the laboratory fasted and not having performed any exercise within 24 h of the study. Sugawara et al., 2003; van Lieshout et al., 2003) . Pulse pressure (PP), a measure of pulsatile arterial afterload, the non-resistive oscillatory component of arterial afterload (Chemla et al., 1998; Kelly et al., 1992) , was calculated as follows: PP (in mmHg) = systolic arterial pressure (SAP) minus diastolic arterial pressure (DAP). Total arterial compliance (TAC), an index of pulsatile arterial afterload that takes into account the effect of SV (Chemla et al., 1998; Reil et al., 2013) was calculated as follows: Total arterial compliance (in mmHg) = SV/PP. Mean arterial pressure was calculated as follows: MAP (in mmHg) = DAP + (PP × 0.33). End-systolic arterial pressure (P es ) was calculated as follows : P es (in mmHg) = 0.9 × SAP. Cardiac output was calculated as follows: CO (in l min −1 ) = SV × HR. Systemic vascular conductance, a measure of systemic vascular tone and the non-pulsatile (mean resistive) component of arterial afterload , was calculated as follows: SVC (in ml min mmHg −1 ) = CO/MAP. Systemic vascular resistance (SVR) was calculated as follows: SVR (in mmHg l min −1 ) = MAP/CO. Effective arterial elastance, an index of total arterial afterload (both pulsatile and non-pulsatile arterial afterload; Kelly et al., 1992; Reil et al., 2013) was calculated as follows: Ea (in mmHg ml −1 ) = P es /SV. Stroke work (SW), a measure of functional left ventricular systolic work Sunagawa, Maughan, & Sagawa, 1985) , was calculated as follows: SW (in mmHg ml) = P es × SV. Rate-pressure product (RPP), an index of myocardial oxygen consumption (Kitamura, Jorgensen, Gobel, Taylor, & Wang, 1972) , was calculated as follows: RPP (in a.u.) = SAP × HR.
Handgrip exercise and metaboreceptor activation
Near-infrared spectroscopy
To determine muscle microvascular deoxyhaemoglobin (DeLorey, Kowalchuk, & Paterson, 2003) during exercise and metaboreceptor activation, in a subset of subjects (HFrEF, n = 13; control, n = 9), near-infrared spectroscopy (NIRS) measurements were made in the brachioradialis and the flexor carpi radialis muscles. A frequencydomain multidistance NIRS system was used (Oxiplex TS; ISS, Champaign, IL, USA) that allows the absolute quantification of deoxyhaemoglobin concentrations, expressed as micromolar (Hueber et al., 2001) . Before use, the probe was calibrated using a block with known absorption characteristics to calculate the absorption and scattering coefficients. Before placement, the skin covering the brachioradialis and the flexor carpi radialis was cleaned, and doublesided adhesive tape was used to seat the diode, which was covered and further secured with coban (3M, St Paul, MN, USA). The data were acquired at 0.5 Hz, and 1 min averages were calculated during the last minute of each exercise bout and during the final minute of PECO.
Data analysis
Statistics were performed using commercially available software (SigmaStat 3.10; Systat Software, Point Richmond, CA, USA). For both the exercise and metaboreceptor activation portion of the protocol, a 2 × 4 repeated-measures ANOVA ( < 0.05) (group, two levels, control versus HFrEF; workload or metaboreflex activation, four levels, rest, 15, 30 and 45% of MVC) was used to determine the exercise-and metaboreflex-induced alterations in haemodynamic measurements.
The Holm-Sidak method was used for adjustment and post hoc analysis.
RESULTS
Subject characteristics
Baseline characteristics of the control subjects and HFrEF patients are displayed in Table 1 . Disease-specific characteristics and medications of patients with HFrEF are presented in Table 2 . Handgrip MVC force
TA B L E 1 Subject characteristics
Characteristic
Control subjects (n = 15) Abbreviations: HFrEF, heart failure with reduced ejection fraction; HDL, high-density lipoprotein; and LDL, low-density lipoprotein. Data are expressed as means ± SD. *Significant difference from control, P < 0.05.
TA B L E 2 Disease-specific characteristics and medications
HFrEF patients (n = 23) Abbreviations: ACE, angiotensin-converting enzyme; HFrEF, heart failure with reduced ejection fraction; and NYHA, New York Heart Association.
was similar between control subjects (27 ± 6 kg) and patients with HFrEF (25 ± 7 kg).
Rest and exercise haemodynamics
Cardiac and peripheral vascular haemodynamics for both groups are presented in Table 3 . At rest, there were no significant differences in deoxyhaemoglobin, MAP, CO or SVC in HFrEF patients compared with control subjects. Exercise elicited similar intensity-dependent increases in deoxyhaemoglobin and MAP between groups. The changes in MAP were dictated by increases in CO across workloads in control subjects and by reductions in SVC in HFrEF patients.
This was complemented by substantially attenuated increases in SAP and exaggerated increases in DAP in HFrEF patients compared with control subjects. These blood pressure differences resulted in a lower PP across exercise intensities in HFrEF patients compared with control subjects. However, when factoring in the differences in SV on PP, as expressed by TAC, there were no significant differences in TAC between groups at any workload. The Ea was significantly increased across all workloads in both groups, but the increases were significantly greater in HFrEF patients compared with control subjects at the two highest workloads. Stroke work increased significantly across all workloads in the control subjects, with no significant difference from rest demonstrated by the HFrEF patients. In contrast, RPP was similar across all workloads in both groups.
Metaboreflex-induced changes in haemodynamics
Cardiac and peripheral vascular haemodynamics during metaboreceptor activation via PECO are presented in Table 4 . (Table 4) . This led to a significantly attenuated increase PP in the patients with HFrEF, who established an increase in PP only at the highest level of metaboreceptor activation.
However, when factoring in the significantly greater increases in SV induced by the metaboreflex exhibited by the control subjects compared with HFrEF patients (expressed as TAC), no difference was evident between groups at any level of metaboreceptor activation (Table 4) . Metaboreceptor activation provoked minimal increases in Ea in control subjects, who exhibited a significant increase only at the highest level (Figure 2 ). In contrast, HFrEF patients had significant increases in Ea across all levels of metaboreceptor activation and were significantly different from control subjects at the highest two levels Total arterial compliance (ml mmHg −1 ) 1.8 ± 0.6 1.6 ± 0.3 1.6 ± 0.7 1.4 ± 0.6 † Effective arterial elastance (mmHg ml −1 ) 1 . 4 ± 0.6 1.6 ± 0.7 † 1.6 ± 1.0* , † 1.8 ± 0.9* , † Heart rate (beats min −1 ) 67 ± 9* 68 ± 11* 70 ± 11* 68 ± 2* Stroke volume (ml beat 
DISCUSSION
In the present study, we sought to examine comprehensively the muscle metaboreflex in HFrEF patients and healthy control subjects of a similar age, with an emphasis on investigating the cardiac and peripheral vascular haemodynamic contributions to the metaboreflexinduced pressor response. Across multiple levels of metaboreceptor activation, the increase in MAP was similar between groups, providing new evidence refuting a disease-related exaggeration of the muscle metaboreflex-induced pressor response in HFrEF. However, a disease-specific, discrete pattern of cardiac and peripheral vascular haemodynamic changes was observed between groups. In control subjects, the pressor response induced by metaboreceptor activation was driven by an increase in CO, with no significant change in SVC.
In contrast, progressively greater reductions in SVC contributed to the pressor response in patients with HFrEF, whereas CO remained Piepoli, Volterrani, & Poole-Wilson (1994) and Piepoli et al. (1999) have hypothesized that abnormalities in sensory reflex activity in skeletal muscle might contribute to the exercise limitations in HFrEF, the so-called 'muscle hypothesis' of heart failure. Located within the skeletal muscle are two distinct sensory afferent fibre types, namely the group III afferent fibres, which are predominately mechanically sensitive (mechanoreceptors) and the group IV afferent fibres (metaboreceptors), which are principally sensitive to metabolites produced during exercise (Kaufman & Hayes, 2002) . Collectively, these reflex pathways serve to increase sympathetic nervous system activity, which ultimately increases perfusion pressure (Amann et al., 2011; Crisafulli et al., 2007; O'Leary & Augustyniak, 1998) . In
Metaboreflex contribution to the exercise-induced changes in MAP
HFrEF patients, some aspect of this reflex response appears to be dysfunctional.
Although it is difficult to isolate these respective reflex pathways completely, PECO has become a widely adopted experimental approach whereby metabolic byproducts produced during exercise are trapped distal to the point of occlusion, activating group IV afferent Metaboreceptor Activation (%MVC) Metaboreflex-Induced Change in Effective Arterial Elastance (ΔmmHg/ml) F I G U R E 2 Metaboreflex-induced changes in effective arterial elastance in control subjects and heart failure patients with reduced ejection fraction (HFrEF). * Significant difference from control, P < 0.05 fibres with minimal input from the group III fibres (Alam & Smirk, 1937) . Interestingly, despite extensive use of this technique over the past 80 years in both healthy humans and patient populations, the exact role of metaboreceptor activation in the cardiovascular response to exercise in HFrEF remains a topic of ongoing debate. Indeed, using microneurography for direct assessment of muscle sympathetic nerve activity (MSNA), evidence can be found for blunted (Sterns et al., 1991) , similar (Middlekauff et al., 2004) and increased (Notarius et al., 2001 ) activity during PECO in HFrEF patients compared with healthy individuals. Likewise, evidence exists for both similar (Carrington et al., 2001; Kon et al., 2004; Notarius et al., 2001; Sterns et al., 1991) and exaggerated (Piepoli & Coats, 2007; Piepoli et al., 1996 Piepoli et al., , 1999 Shoemaker et al., 1998; Silber et al., 1998) reflex increases in MAP during metaboreflex activation in HFrEF patients, indicating that significant uncertainty remains as to whether the metaboreflexinduced pressor response is altered in this patient group.
In the present study, we used the PECO technique after three different handgrip exercise intensities in an effort to evaluate the muscle metaboreflex comprehensively in HFrEF patients compared with healthy control subjects of a similar age. As illustrated in Figure 1 (top panel), we observed a metaboreflex-induced pressor response that was almost identical between groups across all levels of metaboreceptor activation. These results are in disagreement with some of the earliest work on this topic (Piepoli et al., 1999; Shoemaker et al., 1998) and might be explained by differences in experimental protocols, including differing handgrip exercise protocols and methods of activating the muscle metaboreflex (PECO versus limb positive pressure). To our knowledge, the present study is the first to investigate PECO after multiple intensities of staticintermittent handgrip exercise, providing a comprehensive and systematic assessment of the pressor response across multiple levels of metaboreceptor activation. The present findings thus confirm and extend observations from previous work (Carrington et al., 2001; Kon et al., 2004; Notarius et al., 2001; Sterns et al., 1991) , providing new evidence that refutes a disease-related exaggeration of the pressor response induced by the muscle metaboreflex in patients with HFrEF.
Cardiac and peripheral vascular haemodynamic contributions to metaboreflex-induced changes in MAP
Although a large number of studies have focused on elucidating the strength of the metaboreflex-induced pressor response in HFrEF, limited work has been undertaken to examine the variables contributing to this rise in MAP. In a healthy animal model, Augustyniak et al. (2001) documented that the rise in MAP triggered by metaboreceptor activation was achieved via two distinct, but complimentary, mechanisms. Specifically, during mild and moderate exercise intensities, the increase in MAP was attributable solely to increases in CO, with a shift towards a reliance on SVC to increasey MAP only during high-intensity exercise, when the ability to increase CO was compromised. In contrast to this somewhat dichotomous response, work from the same group reported that the metaboreflexinduced increases in MAP in an animal model of systolic HF were primarily attributable to reductions in SVC (Hammond et al., 2000) , indicating that the pressor response was achieved almost exclusively via sympathetic vasoconstriction of the peripheral vasculature. Based on these findings, the authors concluded that the inability of the metaboreflex to increase CO in this animal model of HF is likely to be detrimental, because only a single mechanism appears to be available for this reflex pathway to increase perfusion pressure and, ultimately, blood flow to exercising skeletal muscle.
The present study builds upon the previous findings to human 
Arterial afterload and left ventricular systolic function
The manner by which metaboreceptor activation elicits an increase in MAP may be particularly significant when considering the relationship between the left ventricle and the peripheral vasculature in HFrEF patients. Indeed, SVC represents the non-pulsatile component of arterial afterload Yin & Avolio, 1987) , and it is well established that patients with HFrEF are afterload sensitive (Asanoi et al., 1989; Kameyama et al., 1991; Schwartzenberg et al., 2012) . Thus, these patients face certain impairment in left ventricular systolic function if arterial afterload is increased (Kameyama et al., 1991) . In the present study, at all levels of metaboreceptor activation, HFrEF patients exhibited an exaggerated increase in Ea, an index of total arterial afterload, compared with control subjects, who exhibited a significant augmentation in Ea only at the highest level of metaboreceptor activation (Figure 2 ). As there were no differences between groups in the reduction in TAC (Table 4) 
Experimental considerations
The present study is not without limitations. We acknowledge that the arterial afterload calculations used in the present study are typically based on aortic pressure measurements , and this variable was calculated from measurements obtained noninvasively via finger photoplethysmography in the present study.
Although peripheral ABP measurements may not always reflect central pressures, owing to wave amplification descending the arterial tree (Safar, Protogerou, & Blacher, 2009; Williams et al., 2006) , central ABP measurements may also be augmented as a result of reflected pressure waveforms (Safar et al., 2009) , limiting the discrepancy between central and peripheral pressure measurements Kroeker & Wood, 1955; Nussbacher et al., 1999) . Although effective arterial elastance has been used as an index of total arterial afterload in many studies with diverse clinical populations (Borlaug & Kass, 2008; Borlaug, Lam, Roger, Rodeheffer, & Redfield, 2009; Eleid, Nishimura, Sorajja, & Borlaug, 2013; Kussmaul, Altschuler, Matthai, & Laskey, 1993; Schwartzenberg et al., 1998) , we recognize that this index has not been validated directly in HFrEF patients. Recent evidence suggests that the cardiovascular response to metaboreflex activation is also abnormal in heart failure patients with a preserved ejection fraction (Roberto et al., 2017) ; findings that are relevant to the present study given that many patients with systolic dysfunction also suffer from some level of diastolic dysfunction, ranging from abnormal relaxation to restrictive filling (Lang, Goldstein, Kronzon, Khandheria, & Mor-Avi, 2015; Naqvi, 2003) . However, patients in the present study did not demonstrate any echocardiographic evidence of diastolic dysfunction as defined by current guidelines (Nagueh et al., 2016) , suggesting that the reported findings are specific to the HFrEF phenotype. We enrolled HFrEF patients on optimized pharmacotherapy, and no medications were withheld on experimental days. We therefore cannot exclude the possibility that existing drug therapy might have affected our measurements, particularly cardiac responses, although it is noteworthy that this represents the 'real world' , in which optimally medicated patients live. Finally, we acknowledge that use of the Modelflow method for estimation of stroke volume might not provide the same level of precision as that provided by more invasive techniques, although it is noteworthy that good agreement in tracking CO changes has recently been documented with these two methodologies in heart disease patients (de Wilde, Schreuder, van den Berg, & Jansen, 2007) .
Conclusions
In the present study, we identify a preserved role of the metaboreflexinduced pressor response in HFrEF patients and provide evidence that the rise in MAP is governed almost entirely by the peripheral circulation in this patient population. The net effect of this response appears to be maladaptive, as it places a substantial haemodynamic load on the heart, exacerbates the underlying impairment of systolic function and is likely to contribute to exercise intolerance in this patient group.
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